Download

Full Text

See more details

Policy documents (1)

X (1)

Clinical guidelines (1)

Mendeley (59)

89

CITATIONS

89 Total citations

4 Recent citations

14 Field Citation Ratio

2.43 Relative Citation Ratio

publications

87

supporting

2

mentioning

36

contrasting

0

Smart Citations

87

2

36

0

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

• Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24:5091-5097.
• Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med 2007; 357:2696-2705.
• Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22:2942-2953.
• Ghanem N, Uhl M, Brink I, Schafer O, Kelly T, Moser E, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CTand PET/CTfor the detection of metastases of bone. Eur J Radiol 2005; 55:41-55.
• Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 2009; 10:606-614.
• Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006; 107:2545-2551.
• Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008; 26:712-720.
• Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34:274-292.
• Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009; 39:396-407.
• Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008; 35:1766-1774.
• Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962; 3:332-334.
• Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med 2001; 31:28-49.
• Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PETwith 18F-fluoride: applying newtechnology to an old tracer. J Nucl Med 2008; 49:68-78.
• Petren-Mallmin M, Andreasson I, Ljunggren O, Ahlstrom H, Bergh J, Antoni G, et al. Skeletal metastases from breast cancer: uptake of 18F- fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 1998; 27:72-76.
• Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kuhn T, Kreienberg R, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999; 17:2381-2389.
• Schirrmeister H, Guhlmann A, Elsner K, Kotzerke J, Glatting G, Rentschler M, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999; 40:1623-1629.
• Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42:1800-1804.
• Hetzel M, Arslandemir C, Konig HH, Buck AK, Nussle K, Glatting G, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res 2003; 18:2206-2214.
• Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experiencewith 18F-fluoride PET/CTand comparison between 18F-fluoride PETand 18F-fluoride PET/CT. J Nucl Med 2004; 45:272-278.
• Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47:287-297.
• Ndlovu X, George R, Ellmann A, Warwick J. Should SPECT-CT replace SPECT for the evaluation of equivocal bone scan lesions in patients with underlying malignancies? Nucl Med Commun 2010; 31:659-665.
• Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 1998; 209:253-258.
• Iagaru A, Mittra E, Yaghoubi SS, Dick DW, Quon A, Goris ML, et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med2009; 50:501-505.
• Kruger S, BuckAK, Mottaghy FM, Hasenkamp E, Pauls S, Schumann C, et al. Detection of bone metastases in patients with lung cancer: (99m)Tc-MDP planar bone scintigraphy, (18)F-fluoride PETor (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging 2009; 36:1807-1812.
• Nakamoto Y, Cohade C,Tatsumi M, Hammoud D, Wahl RL. CTappearance of bone metastases detected with FDG PET as part of the same PET/CT examination. Radiology2005; 237:627-634.